Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | DRD1 | P21728 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29384926 | 1.00 | LMNA (0.37) | LMNAMAPTALDH1A1TSHRMEN1 | |
| SCHEMBL25339260 | 0.95 | LMNA (0.34) | LMNAMAPTALDH1A1TSHRMEN1 | |
| SCHEMBL25982014 | 0.89 | ALDH1A1 (0.40) | LMNAMAPTALDH1A1TSHRMEN1 | |
| SCHEMBL31234941 | 0.87 | PIK3CD (0.39) | LMNAMAPTALDH1A1TSHRMEN1 | |
| SCHEMBL31196081 | 0.85 | PIK3CA (0.37) | LMNAMAPTALDH1A1TSHRMEN1 | |
| SCHEMBL21734048 | 0.85 | PIK3CD (0.42) | LMNAMAPTALDH1A1TSHRMEN1 | |
| SCHEMBL25982118 | 0.83 | LMNA (0.41) | LMNAMAPTALDH1A1TSHRMEN1 | |
| SCHEMBL26694550 | 0.83 | QPCT (0.38) | LMNAMAPTALDH1A1TSHRMEN1 | |
| SCHEMBL31380892 | 0.82 | PIK3CD (0.36) | LMNAMAPTALDH1A1TSHRMEN1 | |
| SCHEMBL30142533 | 0.81 | TSPO (0.39) | MAPTALDH1A1MEN1KMT2ATSPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3746436-B1 | FUSED RING COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2026-05-20 | — | — | EP | disclosed |
| US-20260062425-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-20260008787-A1 | FUSED RING KRAS INHIBITORS FOR TREATING DISEASE | BLOSSOMHILL THERAPEUTICS INC (US) | 2026-01-08 | — | — | US | disclosed |
| US-12448400-B2 | KRAS G12D modulating compounds | GILEAD SCIENCES, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-12338256-B2 | Aza-tetracyclic oxazepine compounds and uses thereof | GENENTECH, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| US-20250136621-A1 | KRAS G12D MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2025-05-01 | — | — | US | disclosed |
| US-20250109147-A1 | KRAS G12D MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2025-04-03 | — | — | US | disclosed |
| US-20250101042-A1 | KRAS G12D MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2025-03-27 | — | — | US | disclosed |
| WO-2025054347-A1 | KRAS G12D MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| US-20250059208-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2025-02-20 | — | — | US | disclosed |
| US-11760744-B2 | Fused ring compounds | GENENTECH, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| WO-2023173014-A1 | KRAS INHIBITORS AND THEIR USE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| WO-2023173014-A1 | KRAS INHIBITORS AND THEIR USE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| US-20230250074-A1 | PROCESS FOR SYNTHESIS OF QUINAZOLINE COMPOUNDS | GENENTECH, INC. (US) | 2023-08-10 | — | — | US | disclosed |
| US-20230250074-A1 | PROCESS FOR SYNTHESIS OF QUINAZOLINE COMPOUNDS | GENENTECH, INC. (US) | 2023-08-10 | — | — | US | disclosed |
| US-20230002345-A1 | FUSED RING COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-01-05 | — | — | US | disclosed |
| US-20220281893-A1 | TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2022-09-08 | — | — | US | disclosed |
| US-20220281893-A1 | TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2022-09-08 | — | — | US | disclosed |
| WO-2022173678-A1 | TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2022-08-18 | — | — | WO | disclosed |
| WO-2020035031-A1 | FUSED RING COMPOUNDS | GENENTECH, INC. (US) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250101042-A1 | KRAS G12D MODULATING COMPOUNDS | KRAS, NRAS, HRAS | LMNA 3783/4885MAPT 3007/4885ALDH1A1 4243/4885 |
| US-12338256-B2 | Aza-tetracyclic oxazepine compounds and uses thereof | AZI2, TET3, OXA1L | LMNA 4245/4885MAPT 3374/4885ALDH1A1 1000/4885 |
| US-11760744-B2 | Fused ring compounds | KRAS, NRAS, HRAS | LMNA 3608/4885MAPT 3269/4885ALDH1A1 3678/4885 |
| US-20220281893-A1 | TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | OXA1L, CACNA1I, GRIK5 | LMNA 3975/4885MAPT 1359/4885ALDH1A1 1402/4885 |
| US-20230002345-A1 | FUSED RING COMPOUNDS | KRAS, NRAS, HRAS | LMNA 3608/4885MAPT 3269/4885ALDH1A1 3678/4885 |
| US-20230250074-A1 | PROCESS FOR SYNTHESIS OF QUINAZOLINE COMPOUNDS | HCCS, NQO2, SQLE | LMNA 2878/4885MAPT 3788/4885ALDH1A1 3225/4885 |
| US-20260008787-A1 | FUSED RING KRAS INHIBITORS FOR TREATING DISEASE | KRAS, NRAS, HRAS | LMNA 3062/4885MAPT 4557/4885ALDH1A1 2043/4885 |
| US-20260062425-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | KRAS, NRAS, HRAS | LMNA 3592/4885MAPT 4847/4885ALDH1A1 908/4885 |
| US-12448400-B2 | KRAS G12D modulating compounds | KRAS, NRAS, HRAS | LMNA 3783/4885MAPT 3007/4885ALDH1A1 4243/4885 |
| US-20250136621-A1 | KRAS G12D MODULATING COMPOUNDS | KRAS, NRAS, HRAS | LMNA 3783/4885MAPT 3007/4885ALDH1A1 4243/4885 |
| US-20250109147-A1 | KRAS G12D MODULATING COMPOUNDS | KRAS, NRAS, HRAS | LMNA 3783/4885MAPT 3007/4885ALDH1A1 4243/4885 |
| US-20250059208-A1 | KRAS MODULATING COMPOUNDS | KRAS, NRAS, HRAS | LMNA 3815/4885MAPT 3563/4885ALDH1A1 4252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.